Baudax Bio, Inc. announced that On October 2, 2023, Jillian Dilmore, the Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Baudax Bio, Inc. notified the Company of her decision to resign effective as of October 9, 2023. Ms. Dilmore resigned for personal reasons and not as a result of any disagreement with the Company or its independent registered public accountants on any matter relating to the Company?s financial or accounting operations, policies or practices. Ms. Dilmore has agreed to provide continued consulting support to the Company.

On October 5, 2023, the board of directors of the Company appointed Natalie McAndrew as Interim Chief Financial Officer, effective as of the Effective Date. Ms. McAndrew will also assume the duties of the Principal Financial Officer and Principal Accounting Officer of the Company as of the Effective Date. Beginning on the Effective Date, Ms. McAndrew will provide her services as a consultant through Danforth Advisors, LLC, at an agreed upon hourly rate.

Ms. McAndrew, age 49, is a Director with Danforth, an advisory firm focused on providing financial strategy to life science organizations, and has been employed with Danforth since August 2021. Prior to Danforth, Ms. McAndrew was the VP, Corporate Controller of Tmunity Therapeutics, Inc., a biotechnology company, from January 2021 to July 2021. Ms. McAndrew previously served as Head of Accounting Operations at Spark Therapeutics, Inc., a biotechnology company, from March 2015 until January 2021.

Prior to this, Ms. McAndrew served as Corporate Controller for over 8 years in other privately held and public companies at various life cycle stages, managing finance, accounting, and other corporate operational functions. Ms. McAndrew is a certified public accountant and holds a B.S. degree in Accounting from King?s College.